advertisement
Abstract #27774 Published in IGR 13-1
Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter
Shemesh G; Moisseiev E; Lazar M; Kesler AJournal of Cataract and Refractive Surgery 2011; 37: 486-489
PURPOSE: To evaluate the effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter under light and dark luminance conditions. SETTING: Ophthalmology Department, Tel Aviv Medical Center, Tel Aviv, Israel. DESIGN: Case series. METHODS: The pupil diameter was measured with a Colvard pupillometer in eyes of healthy volunteers under light (5.0 candelas [cd]/m(2)) and dark (0.0 cd/m(2)) luminance conditions before brimonidine 0.10% instillation and after 30 minutes, 3 hours, and 6 hours. RESULTS: The mean age of the 26 volunteers (52 eyes) was 34.73 years (range 19 to 60 years). Under light conditions, the mean pupil diameter was 4.98 mm ± 0.83 (SD) before instillation of brimonidine 0.10% and 4.64 ± 0.82 mm after instillation. The difference was not statistically significant, with 13.4% of eyes having a clinically significant reduction (>1.0 mm) in pupil diameter after 6 hours. Under dark conditions, the mean pupil diameter was 6.76 ± 1.08 mm before instillation of brimonidine 0.10% and 5.30 ± 0.85 mm after instillation; the difference was statistically significant (P<.001). There was a clinically significant reduction in pupil diameter after 6 hours in 90.4% of eyes. The antimydriatic effect under dark luminance conditions was more pronounced in eyes with light irides. CONCLUSIONS: Brimonidine 0.10% ophthalmic solution had an antimydriatic effect under dark luminance conditions and had a negligible effect on pupil diameter under light luminance conditions. The effect was similar to that reported in studies using higher concentrations of brimonidine.
From the Department of Ophthalmology, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
2.8 Iris (Part of: 2 Anatomical structures in glaucoma)